Version history

{
  "content_md": "# Amyotrophic Lateral Sclerosis (ALS)\n\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the selective degeneration of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord. First described by Jean-Martin Charcot in 1869, ALS leads to muscle weakness, spasticity, paralysis, and typically fatal respiratory failure within 2–5 years of symptom onset. The disease affects approximately 3–5 per 100,000 individuals worldwide, with most cases being sporadic (90–95%) while 5–10% are familial with inherited mutations. ALS exists on a spectrum with frontotemporal dementia (FTD), with 10–15% of ALS patients developing FTD and a larger proportion showing subtle cognitive or behavioral changes, reflecting shared neuropathology involving TDP-43 protein aggregation.\n\nThe epidemiological features of ALS include a peak onset age of 58–63 years for sporadic cases and slightly earlier for familial forms. Men are affected slightly more than women (ratio approximately 1.5:1), though this difference diminishes with age. Geographic clusters have been identified, including the Chamorro population of Guam and the Kii Peninsula of Japan, where ALS-Parkinsonism-dementia complex occurs at extraordinarily high rates, suggesting environmental and genetic interaction factors. Approximately 5–10% of ALS cases are linked to specific gene mutations, with the most common being a hexanucleotide repeat expansion in the C9ORF72 gene (40–50% of familial ALS), followed by mutations in SOD1 (15–20%), TARDBP (encoding TDP-43, 5–10%), and FUS (5%).\n\n## Function/Biology\n\nMotor neurons are large, highly specialized cells with extraordinarily long axons that can extend over a meter in length, presenting unique challenges for protein homeostasis, axonal transport, and metabolic support. Upper motor neurons in the layer V pyramidal cells of the motor cortex send corticospinal axons through the internal capsule, brainstem, and spinal cord to synapse onto lower motor neurons, which then project to skeletal muscle fibers at the neuromuscular junction. This Upper-to-Lower motor neuron circuit controls voluntary movement, posture, and breathing.\n\nMotor neuron survival depends on several critical cellular programs including neurotrophic factor signaling (BDNF, GDNF, IGF-1), precise calcium buffering (calcium-binding proteins such as parvalbumin and calbindin), efficient glutamate neurotransmission (with astrocytes normally providing protective glutamate uptake via EAAT2/GLT-1), and robust axonal transport machinery (kinesins, dynein, and associated proteins). Neuromuscular junctions undergo continuous remodeling through the ALS-related proteins MuSK and RAPSN, and motor neurons exhibit exceptionally high metabolic demands with significant mitochondrial activity concentrated at nodes of Ranvier and synaptic terminals.\n\n## Role in Neurodegeneration\n\nALS represents a prototypic example of non-cell-autonomous neurodegeneration, where multiple cell types beyond motor neurons contribute to disease progression. Astrocytes in ALS lose their normal protective functions and acquire toxic properties, releasing inflammatory mediators and failing to clear extracellular glutamate, leading to excitotoxic motor neuron damage. Microglia become chronically activated, producing pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that accelerate motor neuron death. Oligodendrocytes also degenerate early in ALS, depriving motor neurons of metabolic support as these cells normally provide lactate through monocarboxylate transporters.\n\nThe connection between ALS and frontotemporal dementia centers on TDP-43 (encoded by TARDBP), which forms cytoplasmic inclusions in over 95% of ALS cases and approximately 50% of FTD cases. This pathological overlap and the discovery that mutations in TARDBP, C9ORF72, FUS, and TBK1 cause both diseases indicates a shared mechanistic basis involving disrupted RNA metabolism, protein homeostasis, and stress granule dynamics. The spectrum concept recognizes that these diseases represent varying manifestations of a common neurodegenerative process targeting specific neuronal populations.\n\n## Molecular Mechanisms\n\nMultiple interconnected pathological cascades contribute to motor neuron death in ALS. **Oxidative stress** accumulates from mitochondrial dysfunction, with mutated SOD1 proteins exhibiting altered enzymatic activity that promotes reactive oxygen species generation. SOD1 mutations (over 200 identified) cause toxic gain-of-function including mitochondrial recruitment, ER stress activation, and impairment of the proteasome and autophagy-lysosome systems. **Excitotoxicity** results from impaired astrocytic glutamate uptake through EAAT2, leading to excessive calcium influx through AMPA and NMDA receptors and activation of calpains and other calcium-dependent degradative enzymes.\n\n**RNA metabolism dysregulation** represents a central mechanism, particularly for TDP-43 and FUS, which are RNA-binding proteins controlling alternative splicing, mRNA transport, and translation regulation. TDP-43 pathology shows cytoplasmic mislocalization, hyperphosphorylation, and aggregation, with the C-terminal fragments forming insoluble inclusions. The C9ORF72 hexanucleotide repeat expansion (GGGGCC) causes disease through both loss-of-function (reduced C9ORF72 protein expression) and gain-of-function mechanisms including the translation of dipeptide repeat proteins that accumulate in neuronal inclusions, sequestration of RNA-binding proteins, and nucleolar stress.\n\n**Autophagy and mitophagy impairment** contributes significantly, with mutations in autophagy receptors OPTN and TBK1 found in ALS cases. The mTOR pathway is dysregulated, and restoring autophagy through mTOR-independent mechanisms shows therapeutic promise in animal models. **Nuclear factor-κB (NF-κB) and c-Jun signaling** become chronically activated in ALS, driving inflammatory gene expression in microglia and contributing to motor neuron vulnerability.\n\n## Clinical/Research Significance\n\nALS diagnosis relies on clinical examination, electromyography showing widespread denervation and reinnervation patterns, and exclusion of mimicking conditions through neuroimaging and laboratory studies. The revised El Escorial and Awaji criteria provide diagnostic classifications (definite, probable, laboratory-supported probable, possible) based on clinical signs and electrophysiological evidence of upper and lower motor neuron involvement in multiple body regions. Current FDA-approved treatments include **riluzole** (sodium channel blocker and glutamate antagonist, providing 2–3 month survival benefit), **edaravone** (free radical scavenger, beneficial in early-stage patients), and the recently approved **AMX0035** (combination of sodium phenylbutyrate and taurursodiol targeting ER stress and mitochondrial dysfunction).\n\n Numerous therapeutic approaches are in clinical trials including antisense oligonucleotides targeting SOD1 (tofersen) and C9ORF72 repeat expansions, gene therapies delivering neurotrophic factors, stem cell transplantation approaches, and immunotherapies targeting TDP-43 or inflammatory pathways. Biomarker research focuses on neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) in blood and CSF, which correlate with disease progression and are being validated for diagnostic and prognostic use. The ALS research community increasingly recognizes the importance of好运娱乐平台 genetic stratification and biomarker-driven patient selection for clinical trials to improve the historically low translation rate from preclinical to clinical efficacy.\n\n## Related Entities\n\nKey genes and proteins implicated in ALS include **C9ORF72** (hexanucleotide repeat expansion, most common familial cause), **SOD1** (superoxide dismutase 1, first identified ALS gene), **TARDBP/TDP-43** (DNA-binding protein regulating RNA metabolism), **FUS** (Fused in Sarcoma, TLS, another RNA-binding protein), **OPTN** (optineurin, autophagy receptor), **TBK1** (TANK-binding kinase 1, regulating inflammation and autophagy), and **ATXN2** (ataxin 2, RNA granules and stress response). Related neurodegenerative diseases include **Frontotemporal Dementia (FTD)**, **Alzheimer's Disease**, **Parkinson's Disease**, and **Huntington's Disease** as overlapping or interacting proteinopathy contexts. Functional pathway connections link ALS to **mitochondrial dysfunction**, **autophagy impairment**, **excitotoxicity**, and **neuroinflammation**, providing therapeutic target opportunities across multiple mechanistic nodes.\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving Amyotrophic Lateral Sclerosis (ALS) discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    benchmark_ot_ad_answer_key_C9O[\"benchmark_ot_ad_answer_key:C9ORF72\"] -->|\"data in\"| C9orf72[\"C9orf72\"]\n    AMYOTROPHIC_LATERAL_SCLEROSIS[\"AMYOTROPHIC LATERAL SCLEROSIS\"] -->|\"associated with\"| C9orf72[\"C9orf72\"]\n    MMP9[\"MMP9\"] -->|\"regulates\"| C9orf72[\"C9orf72\"]\n    PARKINSON_S_DISEASE[\"PARKINSON'S DISEASE\"] -->|\"increases risk\"| C9orf72[\"C9orf72\"]\n    ALS[\"ALS\"] -->|\"interacts with\"| C9orf72[\"C9orf72\"]\n    TDP_43[\"TDP-43\"] -->|\"encodes\"| C9orf72[\"C9orf72\"]\n    TMEM106B[\"TMEM106B\"] -->|\"activates\"| C9orf72[\"C9orf72\"]\n    UBQLN2[\"UBQLN2\"] -->|\"exacerbates\"| C9orf72[\"C9orf72\"]\n    NEURONS[\"NEURONS\"] -->|\"produces\"| C9orf72[\"C9orf72\"]\n    NEK1[\"NEK1\"] -->|\"exacerbates\"| C9orf72[\"C9orf72\"]\n    MTOR[\"MTOR\"] -->|\"expressed in\"| C9orf72[\"C9orf72\"]\n    ALS[\"ALS\"] -->|\"depleted in\"| C9orf72[\"C9orf72\"]\n    CEREBELLUM[\"CEREBELLUM\"] -->|\"implicated in\"| C9orf72[\"C9orf72\"]\n    CEREBELLUM[\"CEREBELLUM\"] -->|\"participates in\"| C9orf72[\"C9orf72\"]\n    DNA_DAMAGE_RESPONSE[\"DNA DAMAGE RESPONSE\"] -->|\"associated with\"| C9orf72[\"C9orf72\"]\n    style benchmark_ot_ad_answer_key_C9O fill:#4fc3f7,stroke:#333,color:#000\n    style C9orf72 fill:#ce93d8,stroke:#333,color:#000\n    style AMYOTROPHIC_LATERAL_SCLEROSIS fill:#ce93d8,stroke:#333,color:#000\n    style MMP9 fill:#ce93d8,stroke:#333,color:#000\n    style PARKINSON_S_DISEASE fill:#ef5350,stroke:#333,color:#000\n    style ALS fill:#ef5350,stroke:#333,color:#000\n    style TDP_43 fill:#4fc3f7,stroke:#333,color:#000\n    style TMEM106B fill:#ce93d8,stroke:#333,color:#000\n    style UBQLN2 fill:#ce93d8,stroke:#333,color:#000\n    style NEURONS fill:#80deea,stroke:#333,color:#000\n    style NEK1 fill:#ce93d8,stroke:#333,color:#000\n    style MTOR fill:#ce93d8,stroke:#333,color:#000\n    style CEREBELLUM fill:#b39ddb,stroke:#333,color:#000\n    style DNA_DAMAGE_RESPONSE fill:#81c784,stroke:#333,color:#000\n```\n\n",
  "entity_type": "disease",
  "kg_node_id": "C9orf72",
  "frontmatter_json": {
    "tags": [
      "disease",
      "stub",
      "redirect"
    ],
    "title": "Amyotrophic Lateral Sclerosis (ALS)",
    "datecreated": "2026-04-13T14:30:20.750142+00:00",
    "dateupdated": "2026-04-13T14:30:20.750142+00:00",
    "entity_type": "disease"
  },
  "refs_json": [
    {
      "doi": "10.1111/ene.14393",
      "pmid": "32526057",
      "year": 2020,
      "title": "Amyotrophic lateral sclerosis: a clinical review.",
      "authors": [
        "Masrori P",
        "Van Damme P"
      ],
      "journal": "Eur J Neurol"
    },
    {
      "doi": "10.1016/j.jpainsymman.2023.06.029",
      "pmid": "37380145",
      "year": 2023,
      "title": "Palliative Care in Amyotrophic Lateral Sclerosis.",
      "authors": [
        "Mercadante S",
        "Al-Husinat L"
      ],
      "journal": "J Pain Symptom Manage"
    },
    {
      "doi": "10.1016/B978-0-323-98817-9.00031-4",
      "pmid": "37620070",
      "year": 2023,
      "title": "Amyotrophic lateral sclerosis.",
      "authors": [
        "Younger DS",
        "Brown RH Jr"
      ],
      "journal": "Handb Clin Neurol"
    },
    {
      "doi": "10.1097/WCO.0000000000001094",
      "pmid": "35942674",
      "year": 2022,
      "title": "Biomarkers for amyotrophic lateral sclerosis.",
      "authors": [
        "Witzel S",
        "Mayer K",
        "Oeckl P"
      ],
      "journal": "Curr Opin Neurol"
    },
    {
      "doi": "10.1002/mus.27567",
      "pmid": "35607838",
      "year": 2022,
      "title": "Amyotrophic lateral sclerosis mimics.",
      "authors": [
        "Kwan J",
        "Vullaganti M"
      ],
      "journal": "Muscle Nerve"
    },
    {
      "doi": "10.3390/ijms26115240",
      "pmid": "40508048",
      "year": 2025,
      "title": "Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2).",
      "authors": [
        "Tolochko C",
        "Shiryaeva O",
        "Alekseeva T"
      ],
      "journal": "Int J Mol Sci"
    },
    {
      "doi": "10.1186/s13024-023-00685-6",
      "pmid": "38267984",
      "year": 2024,
      "title": "Fluid biomarkers for amyotrophic lateral sclerosis: a review.",
      "authors": [
        "Irwin KE",
        "Sheth U",
        "Wong PC"
      ],
      "journal": "Mol Neurodegener"
    },
    {
      "doi": "10.1007/s00415-025-12975-8",
      "pmid": "40009238",
      "year": 2025,
      "title": "Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects.",
      "authors": [
        "Ruffo P",
        "Traynor BJ",
        "Conforti FL"
      ],
      "journal": "J Neurol"
    },
    {
      "doi": "https://doi.org/10.1038/s41598-016-0001-8",
      "year": 2016,
      "title": "Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease",
      "authors": [
        "Valentina Cappello",
        "Laura Marchetti",
        "Paola Parlanti",
        "Silvia Landi",
        "Ilaria Tonazzini"
      ],
      "journal": "Scientific Reports"
    },
    {
      "doi": "https://doi.org/10.1159/000337115",
      "year": 2012,
      "title": "Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity",
      "authors": [
        "Elisabetta Polazzi",
        "Ilaria Mengoni",
        "Marco Caprini",
        "Emiliano Peña‐Altamira",
        "Ewelina Kurtys"
      ],
      "journal": "Neurosignals"
    },
    {
      "doi": "https://doi.org/10.1152/physrev.00029.2006",
      "year": 2007,
      "title": "Nitric Oxide and Peroxynitrite in Health and Disease",
      "authors": [
        "Pál Pacher",
        "Joseph S. Beckman",
        "Lucas Liaudet"
      ],
      "journal": "Physiological Reviews"
    },
    {
      "doi": "https://doi.org/10.1523/jneurosci.1860-14.2014",
      "year": 2014,
      "title": "An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex",
      "authors": [
        "Ye Zhang",
        "Kenian Chen",
        "Steven A. Sloan",
        "Mariko L. Bennett",
        "Anja R. Scholze"
      ],
      "journal": "Journal of Neuroscience"
    },
    {
      "doi": "https://doi.org/10.1007/s00401-009-0619-8",
      "year": 2009,
      "title": "Astrocytes: biology and pathology",
      "authors": [
        "Michael V. Sofroniew",
        "Harry V. Vinters"
      ],
      "journal": "Acta Neuropathologica"
    },
    {
      "doi": "https://doi.org/10.2147/clep.s91125",
      "year": 2015,
      "title": "The Danish National Patient Registry: a review of content, data quality, and research potential",
      "authors": [
        "Morten Schmidt",
        "Sigrún Alba Jóhannesdóttir Schmidt",
        "Jakob Lynge Sandegaard",
        "Véra Ehrenstein",
        "Lars Pedersen"
      ],
      "journal": "Clinical Epidemiology"
    },
    {
      "doi": "https://doi.org/10.1155/2017/8416763",
      "year": 2017,
      "title": "Oxidative Stress: Harms and Benefits for Human Health",
      "authors": [
        "Gabriele Pizzino",
        "Natasha Irrera",
        "Mariapaola Cucinotta",
        "Giovanni Pallio",
        "Federica Mannino"
      ],
      "journal": "Oxidative Medicine and Cellular Longevity"
    },
    {
      "doi": "https://doi.org/10.1038/s41419-020-2298-2",
      "year": 2020,
      "title": "Ferroptosis: past, present and future",
      "authors": [
        "Jie Li",
        "Feng Cao",
        "He-liang Yin",
        "Zi-jian Huang",
        "Zhi-tao Lin"
      ],
      "journal": "Cell Death and Disease"
    },
    {
      "doi": "10.5772/30426",
      "year": 2012,
      "title": "Communication Impairment in ALS Patients Assessment and Treatment",
      "authors": [
        "Paolo Bongioanni"
      ],
      "journal": "Amyotrophic Lateral Sclerosis"
    },
    {
      "doi": "10.3109/17482968.2011.553796",
      "year": 2011,
      "title": "ALSUntangled No. 9: Blue-green algae (Spirulina) as a treatment for ALS",
      "authors": [
        ""
      ],
      "journal": "Amyotrophic Lateral Sclerosis"
    },
    {
      "doi": "10.1080/146608202760839001",
      "year": 2002,
      "title": "Stem cells in the treatment of amyotrophic lateral sclerosis (ALS)",
      "authors": [
        "Vincenzo Silani",
        "Isabella Fogh",
        "Antonia Ratti",
        "Jenny Sassone",
        "Andrea Ciammola"
      ],
      "journal": "Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"
    },
    {
      "doi": "10.5772/34020",
      "year": 2012,
      "title": "Amyotrophic Lateral Sclerosis: An Introduction to Treatment and Trials",
      "authors": [
        "Martin H."
      ],
      "journal": "Amyotrophic Lateral Sclerosis"
    },
    {
      "doi": "10.53347/rid-96562",
      "year": 2022,
      "title": "Amyotrophic lateral sclerosis (ALS)",
      "authors": [
        "Ammar Haouimi"
      ],
      "journal": "Radiopaedia.org"
    }
  ],
  "epistemic_status": "provisional",
  "word_count": 1073,
  "source_repo": "NeuroWiki"
}